AI-generated summary
The authors reviewed three randomized controlled trials involving 229 head and neck cancer patients receiving chemotherapy or radiotherapy, comparing photobiomodulation with placebo. They report that photobiomodulation may add short-term cost but may be less costly over the medium to long term, and that the treatment group had a lower incidence of severe oral mucositis. The certainty of evidence was rated moderate, and the authors call for more trials using standardized protocols.
- Participants
- 229
- Studies included
- 3
- Who or what was studied
- Patients with head and neck cancer undergoing chemotherapy and/or radiotherapy
- Limits stated in the abstract
- Only three randomized trials were included, the certainty of evidence was rated moderate, and the authors state more trials following standardized protocols are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
We report on the cost-effectiveness of photobiomodulation (PBM) for the prevention and treatment of oral mucositis (OM) derived from the cytotoxic effects of antineoplastic therapy.
Methods
This review followed the PRISMA 2020 guidelines. A search was conducted in PubMed, Scopus, Web of Science, Embase, and OpenGrey. Articles published before 23 July 2024, were included. Randomized controlled trials (RCTs) that included patients with head and neck cancer undergoing chemotherapy and/or radiotherapy and a placebo group compared to an intervention group (PBM) were selected. The risk of bias was evaluated using the Joanna Briggs Institute tools. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach and was rated as moderate.
Results
A total of 3 RCTs and 229 patients were included. PBM may represent an additional cost in the short term, but the incremental expenses derived from the cytotoxic effects of antineoplastic therapy are greater in the medium-long term. The intervention group (PBM) showed a lower incidence of severe OM compared to the control group (placebo).
Conclusions
PBM is a cost-effective long-term treatment, effective in preventing severe OM and improving the quality of life of cancer patients. More RCTs following the same standardized protocols are needed (registration CDR42024498825).
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oral mucositis, Systematic review, Control group, Risk of bias, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.